TITLE

Assessing Response to Treatment in Non-Small-Cell Lung Cancer: Role of Tumor Volume Evaluated By Computed Tomography

AUTHOR(S)
Knollmann, Friedrich D.; Kumthekar, Rohan; Fetzer, David; Socinski, Mark A.
PUB. DATE
March 2014
SOURCE
Clinical Lung Cancer;Mar2014, Vol. 15 Issue 2, p103
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
94754943

 

Related Articles

  • Standard uptake value and metabolic tumor volume of F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Wei Huang; Tao Zhou; Li Ma; Hongfu Sun; Heyi Gong; Juan Wang; Jinming Yu; Baosheng Li // European Journal of Nuclear Medicine & Molecular Imaging;Sep2011, Vol. 38 Issue 9, p1628 

    Purpose: The aim of this study is to investigate the role of standard uptake values (SUVs) and metabolic tumor volume (MTV) in [F]fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) to predict the short-term outcome of chemoradiotherapy (CRT) in patients with...

  • PET/CT in the Staging of the Non-Small-Cell Lung Cancer. Fangfang Chao; Hong Zhang // Journal of Biomedicine & Biotechnology;2012, Vol. 2012, p1 

    Lung cancer is a common disease and the leading cause of cancer-related death in many countries. Precise staging of patients with non-small-cell lung cancer plays an important role in determining treatment strategy and prognosis. Positron emission tomography/computed tomography (PET/CT),...

  • Integrin-Targeted Hybrid Fluorescence Molecular Tomography/X-ray Computed Tomography for Imaging Tumor Progression and Early Response in Non-Small Cell Lung Cancer. Xiaopeng Ma; Van, Valerie Phi; Kimm, Melanie A.; Prakash, Jaya; Kessler, Horst; Kosanke, Katja; Feuchtinger, Annette; Aichler, Michaela; Gupta, Aayush; Rummeny, Ernst J.; Eisenblätter, Michel; Siveke, Jens; Walch, Axel K.; Braren, Rickmer; Ntziachristos, Vasilis; Wildgruber, Moritz // Neoplasia;Jan2017, Vol. 19 Issue 1, p8 

    Integrins play an important role in tumor progression, invasion and metastasis. Therefore we aimed to evaluate a preclinical imaging approach applying ανβ3 integrin targeted hybrid Fluorescence Molecular Tomography/X-ray Computed Tomography (FMT-XCT) for monitoring tumor progression as...

  • Early Proof Possible of Successful Cancer Treatment.  // Pulmonary Reviews;Aug2007, Vol. 12 Issue 8, p18 

    The article reports on the use of positron emission tomography (PET) to assess the success of a cancer radiation treatment. In a study conducted among 15 people with early stage non-small cell lung cancer, fluorodeoxyglucose (FDG) PET was administered before, during and after therapy. A...

  • Imaging.  // Current Medical Literature: Lung Cancer;2007, Vol. 1 Issue 2, p63 

    The article presents studies on lung cancer imaging. A study by F. Taguchi et al published in the "Journal of the National Cancer Institute" discussed the use of mass spectrometry in the classification of non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine...

  • The utility of positron emission tomography in the treatment planning of image-guided radiotherapy for non-small cell lung cancer. Chi, Alexander; Nguyen, Nam P. // Frontiers in Oncology;Oct2014, Vol. 4, p1 

    In the thorax, the extent of tumor may be more accurately defined with the addition of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) to computed tomography (CT). This led to the increased utility of FDG-PET or PET/CT in the treatment planning of radiotherapy for non-small cell...

  • Imaging metrics predicted OS in NSCLC treated with stereotactic ablative radiotherapy.  // Hem/Onc Today;7/10/2013, Vol. 14 Issue 13, p32 

    The article reports that positron emission tomography/computed tomography imaging before treatment can help predict the survival chances of patients with non-small cell lung cancer treated with stereotactic ablative radiotherapy.

  • Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors. Barlési, F.; Balleyguier, C.; Besse, B.; Bonodeau, F.; Brenac, F.; Corneloup, O.; Dansin, E.; Ferretti, G.; Gaubert, J. Y.; Gervais, R.; Lacombe, C.; Loundou, A.; Moro-Sibilot, D.; Planchard, D.; Scherpereel, A.; Menu, Y. // Annals of Oncology;Aug2010, Vol. 21 Issue 8, p1682 

    Background: Bevacizumab (BVZ) combined with platinum-based therapy is registered for first-line treatment of nonsquamous non-small-cell lung cancer (NSCLC). Patients with centrally located tumors are stated ineligible for BVZ treatment. The goal of this study was to assess the consistency in...

  • PET--CT in lung cancer: data discrepancies. Paredes, Jose M.; Mehta, Jayesh // Thorax;Dec2011, Vol. 66 Issue 12, p1092 

    A letter to the editor is presented in response to the Danish study of positron emission tomography (PET)-computer tomography (CT) versus conventional staging (CS) in non-small cell lung cancer.

  • PET--CT in lung cancer: data discrepancies. Fischer, Barbara M.; Mortensen, Jann; Højgaard, Liselotte // Thorax;Dec2011, Vol. 66 Issue 12, p1092 

    A response by Barbara M. Fischer and colleagues to a letter to the editor about their study of positron emission tomography (PET)-computer tomography (CT) versus conventional staging (CS) in non-small cell lung cancer is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics